Location History:
- Chesterfield, MO (US) (2000 - 2002)
- St. Louis, MO (US) (1996 - 2006)
Company Filing History:
21 out of 1,323 
1 out of 33 
1 out of 220 
Years Active: 1996-2006
Title: **Innovative Contributions of Sarah Ruth Braford-Goldberg in Hematopoiesis**
Introduction
Sarah Ruth Braford-Goldberg, an accomplished inventor based in St. Louis, MO, has made significant strides in the field of biomedical innovations. With an impressive portfolio of 31 patents, her work focuses primarily on interleukin-3 (IL-3) variants and their applications in hematopoiesis.
Latest Patents
Among her latest patents, Braford-Goldberg has developed a fusion protein relating to human interleukin-3 (hIL-3) variants. This invention presents fusion molecules composed of hIL-3 mutant proteins that are functionally joined to other colony stimulating factors (CSFs), cytokines, or lymphokines. The hIL-3 variants encompass amino acid substitutions and deletions at both the N- and C-termini, providing a foundation for new pharmaceutical compositions and methodologies.
Another notable patent involves methods of utilizing IL-3 mutant polypeptides for the ex-vivo expansion of hematopoietic stem cells. This invention also emphasizes the development of recombinant human IL-3 muteins, which include various amino acid manipulations. The resultant hIL-3 muteins aim to display biological activities comparable to or improved over the native hIL-3, alongside a potentially enhanced side effect profile.
Career Highlights
Throughout her career, Braford-Goldberg has been affiliated with G.D. Searle & Company, contributing her expertise to the advancement of biopharmaceutical technologies. Her consistent dedication to research and innovation has positioned her as a key figure in her field.
Collaborations
Sarah has collaborated with esteemed coworkers, including John Patrick McKearn and Alan Michael Easton. These partnerships have fostered a creative environment conducive to the development of groundbreaking inventions in hemopoietic research.
Conclusion
In summary, Sarah Ruth Braford-Goldberg exemplifies the spirit of innovation in the biomedical sector. Her extensive patent portfolio underscores her commitment to advancing the understanding and application of interleukin-3 variants. As she continues to explore the potential of her inventions, her impact on hematopoiesis and related medical fields is sure to resonate for years to come.